CMS Excludes Obesity Drugs from Medicare Coverage Amid Cost Concerns
CMS excludes obesity drugs from 2026 Medicare coverage, citing cost concerns; Eli Lilly criticizes the decision impacting obesity management treatments.
Medicare Coverage for Anti-Obesity Drugs Gains Attention in Maine
Maine advocates seek Medicare coverage for anti-obesity medications to improve public health, reduce healthcare costs, and promote active transportation. Bipartisan support grows with Senator Susan Collins' leadership.